Cempra commences CEM-102 Phase 2 trial in prosthetic joint infections Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet up critical medical needs in the treating bacterial infectious illnesses, today announced the initiation of its Stage 2 scientific trial of CEM-102 in sufferers with prosthetic joint attacks .S. Related StoriesAntibiotic resistance possibly threatens the security and efficacy of surgical procedures and immunosuppression therapiesShared decision making between doctors and patients useful in fight against antibiotic resistanceArchbishop of York agrees to be Antibiotic Research UK's Patron The availability of an all-oral antibiotic routine for the treatment of PJI offers the promise of convenient medication administration without the expense and morbidity of keeping long term venous gain access to, stated David Oldach, M.D., FIDSA, senior vice president of clinical study.NPLEx is normally provided at no charge to the state. By passing HB 334, Ohio becomes the 25th condition to adopt the proven system. Since NPLEx was initially launched in 2008, the machine has blocked hundreds-of-thousands of attempted purchases and led to numerous arrests and convictions each year. I commend Representative Johnson and Representative Bupb for the leadership they displayed by shepherding HB 334 through the Ohio House and Senate, stated Scott M. Melville , the president and chief executive officer of the buyer Healthcare Products Association. Ohio now joins 24 states that have adopted real-time, stop-sale technology. Not only does the proven system stop illegal sales of popular allergy and cold medications, it also means that law-abiding consumers continue to get access to the medicines they rely on for rest from cold and allergy symptoms.